Geron Q1 Revenue Rises 8% to $51.8M, Net Loss Narrows to $3.6M
Geron reported $51.8 million in RYTELO net product revenue in Q1 2026, up 8% sequentially and narrowing net loss to $3.6 million. The company reaffirmed 2026 revenue guidance of $220–240 million, projected $230–240 million in operating expenses, and appointed Timothy Williams, Patricia Andrews and Constantine Chinoporos.
1. Q1 Financial Results
Geron delivered $51.8 million in RYTELO net product revenue in Q1 2026, reflecting an 8% sequential increase and 6% demand growth from the prior quarter. Net loss narrowed to $3.6 million from $19.8 million a year earlier, and cash, equivalents and marketable securities totaled $341 million at March 31, 2026.
2. 2026 Financial Guidance
The company reiterated full-year 2026 guidance for RYTELO net product revenue of $220 million to $240 million and total operating expenses of $230 million to $240 million, preserving expectations for disciplined financial performance.
3. Commercial and R&D Highlights
Geron expanded its U.S. commercial reach, increasing ordering accounts by 12% to approximately 1,450, and secured inclusion of imetelstat in NCCN chemotherapy order templates for lower-risk myelodysplastic syndromes. Investigator-sponsored trials and real-world evidence studies are underway, with initial data expected in H2 2026.
4. Leadership and Corporate Developments
Appointments of Timothy Williams as EVP and Chief Legal Officer, alongside Patricia S. Andrews and Constantine Chinoporos to the Board, strengthened corporate leadership. The company also validated a second drug product supplier to bolster RYTELO’s manufacturing supply chain.